Recent research from the University of Hong Kong reveals three critical findings that could reshape treatment for aggressive leukemia cases. First, the QUIZOM combination therapy achieves an 83% complete remission rate in patients with FLT3-mutated acute myeloid leukemia—a condition historically difficult to treat.
Second, the dual-mechanism strategy is particularly innovative: Quizartinib targets cancer cells while Omacetaxine addresses cancer stem cells and simultaneously enhances immune system activation. This multi-pronged approach addresses resistance patterns that single therapies cannot overcome.
Third, and perhaps most practically significant, the therapy extends the critical window for bone marrow transplantation—a transformative procedure previously unavailable to many high-risk patients due to inadequate remission rates. For patients and clinicians, this means expanded treatment options and improved prospects for long-term survival in cases once considered intractable.
Read the full article on GMJ Newsroom.
Was this article helpful?
